Key result
Outpatient respiratory human infection models carry minimal safety risks with 1 recorded transmission event.
Why the study?
Controlled human infection model costs are driven by quarantine facilities, prompting evaluation of the safety, logistic, and ethical risks of outpatient RSV models to support affordable vaccine development.
Are outpatient controlled human infection models (CHIMs) for respiratory pathogens safe regarding third-party transmission?
Systematic Review (n=2,789)
Are outpatient controlled human infection models (CHIMs) for respiratory pathogens safe regarding third-party transmission?
Outpatient controlled human infection models for respiratory pathogens like RSV appear safe with minimal risk of third-party transmission, offering a cost-effective pathway for vaccine development.
Supports safe outpatient CHIM adoption for RSV vaccine trials; extends evidence of minimal transmission to enable affordable development.
Controlled human infection models (CHIMs) are an important tool for accelerating clinical development of vaccines. CHIM costs are driven by quarantine facilities but may be reduced by performing CHIM in the outpatient setting. Furthermore, outpatient CHIMs offer benefits beyond costs, such as a participant-friendly approach and increased real-world aspect. We analyze safety, logistic and ethical risks of respiratory syncytial virus (RSV) CHIM in the outpatient setting. A review of the literature identified outpatient CHIMs involving respiratory pathogens. RSV transmission risk was assessed using data from our inpatient and outpatient RSV CHIMs (EudraCT 020-004137-21). Fifty-nine outpatient CHIMs using RSV, Streptococcus pneumoniae, rhinovirus, and an ongoing Bordetella Pertussis outpatient CHIM were included. One transmission event was recorded. In an inpatient RSV CHIM, standard droplet and isolation measures were sufficient to limit RSV transmission and no symptomatic third-party transmission was measured in the first outpatient RSV CHIM. Logistic and ethical advantages support outpatient CHIM adoption. We propose a framework for outpatient RSV CHIM with risk mitigation strategies to enhance affordable vaccine development.
No takes yet. Share an insight, caveat, or question.
Siegal et al. (2025) conducted a systematic review in Respiratory pathogen infection (RSV, Rhinovirus, Streptococcus pneumoniae) (n=2,789). Outpatient Controlled Human Infection Model (CHIM) was evaluated on Third-party transmission of respiratory pathogens. Outpatient controlled human infection models for respiratory pathogens demonstrated minimal safety risks, with only one recorded transmission event across 59 studies, supporting their use for affordable RSV vaccine development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: